Salmaan A. Keshavjee, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis, Multidrug-Resistant | 42 | 2023 | 942 | 5.800 |
Why?
|
| Tuberculosis | 29 | 2023 | 2013 | 3.730 |
Why?
|
| Antitubercular Agents | 39 | 2023 | 1382 | 3.450 |
Why?
|
| Tuberculosis, Pulmonary | 13 | 2022 | 837 | 2.360 |
Why?
|
| Mycobacterium tuberculosis | 16 | 2023 | 1914 | 1.500 |
Why?
|
| Latent Tuberculosis | 5 | 2023 | 223 | 1.260 |
Why?
|
| Isoniazid | 7 | 2023 | 279 | 1.120 |
Why?
|
| Communicable Disease Control | 3 | 2021 | 856 | 1.060 |
Why?
|
| Prisoners | 4 | 2023 | 315 | 1.000 |
Why?
|
| Peru | 11 | 2023 | 887 | 0.950 |
Why?
|
| Russia | 12 | 2018 | 383 | 0.810 |
Why?
|
| Tuberculosis, Miliary | 1 | 2020 | 13 | 0.730 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 6 | 2015 | 85 | 0.680 |
Why?
|
| Prisons | 2 | 2023 | 178 | 0.670 |
Why?
|
| Delivery of Health Care | 6 | 2021 | 5368 | 0.630 |
Why?
|
| Contact Tracing | 3 | 2020 | 274 | 0.610 |
Why?
|
| Health Policy | 6 | 2022 | 2699 | 0.540 |
Why?
|
| Health Planning Technical Assistance | 1 | 2014 | 5 | 0.480 |
Why?
|
| Disease Transmission, Infectious | 2 | 2018 | 560 | 0.470 |
Why?
|
| Sputum | 4 | 2023 | 513 | 0.450 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 1794 | 0.430 |
Why?
|
| International Agencies | 2 | 2011 | 241 | 0.430 |
Why?
|
| Human Rights | 1 | 2016 | 312 | 0.420 |
Why?
|
| Silicosis | 1 | 2013 | 47 | 0.410 |
Why?
|
| Mining | 1 | 2013 | 93 | 0.400 |
Why?
|
| Vaccination | 2 | 2022 | 3425 | 0.390 |
Why?
|
| Disease Notification | 1 | 2012 | 95 | 0.380 |
Why?
|
| Standard of Care | 1 | 2016 | 567 | 0.380 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2012 | 123 | 0.370 |
Why?
|
| Urban Health Services | 1 | 2012 | 176 | 0.370 |
Why?
|
| Mass Screening | 7 | 2023 | 5445 | 0.370 |
Why?
|
| Health Services Accessibility | 9 | 2022 | 5508 | 0.360 |
Why?
|
| Disease Outbreaks | 4 | 2012 | 1760 | 0.360 |
Why?
|
| Health Services Research | 1 | 2018 | 1811 | 0.360 |
Why?
|
| Fluoroquinolones | 6 | 2021 | 307 | 0.350 |
Why?
|
| Tuberculin Test | 2 | 2020 | 205 | 0.310 |
Why?
|
| Aviation | 1 | 2008 | 49 | 0.290 |
Why?
|
| Drug Therapy, Combination | 8 | 2023 | 6304 | 0.290 |
Why?
|
| Humans | 87 | 2023 | 765823 | 0.280 |
Why?
|
| HIV Infections | 11 | 2022 | 17530 | 0.270 |
Why?
|
| Transportation of Patients | 1 | 2008 | 178 | 0.270 |
Why?
|
| Ethics, Institutional | 1 | 2006 | 38 | 0.270 |
Why?
|
| Pakistan | 5 | 2022 | 300 | 0.270 |
Why?
|
| Rifampin | 4 | 2022 | 350 | 0.270 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 255 | 0.260 |
Why?
|
| Bloodletting | 1 | 2006 | 22 | 0.260 |
Why?
|
| Medicine, Traditional | 1 | 2006 | 88 | 0.250 |
Why?
|
| Health Education | 1 | 2012 | 1060 | 0.250 |
Why?
|
| Clinical Medicine | 1 | 2006 | 145 | 0.240 |
Why?
|
| Occupational Diseases | 1 | 2013 | 1456 | 0.230 |
Why?
|
| Lesotho | 6 | 2012 | 77 | 0.230 |
Why?
|
| Program Evaluation | 4 | 2019 | 2501 | 0.230 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2014 | 592 | 0.220 |
Why?
|
| Economics | 2 | 2006 | 141 | 0.220 |
Why?
|
| Developing Countries | 3 | 2021 | 2913 | 0.220 |
Why?
|
| Telemedicine | 1 | 2021 | 3106 | 0.220 |
Why?
|
| National Health Programs | 2 | 2021 | 443 | 0.210 |
Why?
|
| Biomedical Research | 1 | 2019 | 3457 | 0.210 |
Why?
|
| Social Environment | 1 | 2007 | 1011 | 0.200 |
Why?
|
| Program Development | 2 | 2011 | 1296 | 0.200 |
Why?
|
| Blood-Borne Pathogens | 1 | 2001 | 51 | 0.190 |
Why?
|
| Epidemics | 2 | 2019 | 513 | 0.190 |
Why?
|
| Ethics | 1 | 2001 | 93 | 0.190 |
Why?
|
| Deinstitutionalization | 1 | 2021 | 19 | 0.190 |
Why?
|
| Blood Banks | 1 | 2001 | 108 | 0.180 |
Why?
|
| Adolescent | 19 | 2022 | 88794 | 0.170 |
Why?
|
| X-Rays | 1 | 2021 | 310 | 0.170 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2023 | 335 | 0.170 |
Why?
|
| Violence | 1 | 2006 | 934 | 0.170 |
Why?
|
| Secondary Prevention | 3 | 2016 | 1471 | 0.170 |
Why?
|
| Socioeconomic Factors | 5 | 2022 | 7840 | 0.170 |
Why?
|
| Directly Observed Therapy | 2 | 2012 | 139 | 0.170 |
Why?
|
| Public Health | 6 | 2022 | 2678 | 0.170 |
Why?
|
| Community Health Services | 3 | 2021 | 657 | 0.170 |
Why?
|
| Social Conditions | 2 | 2013 | 119 | 0.160 |
Why?
|
| Healthcare Disparities | 4 | 2022 | 3412 | 0.160 |
Why?
|
| Poverty | 2 | 2007 | 2714 | 0.160 |
Why?
|
| Adult | 31 | 2022 | 223055 | 0.160 |
Why?
|
| Social Responsibility | 1 | 2001 | 382 | 0.150 |
Why?
|
| Ethics, Medical | 1 | 2004 | 784 | 0.150 |
Why?
|
| Transients and Migrants | 1 | 2021 | 170 | 0.150 |
Why?
|
| Clofazimine | 2 | 2018 | 39 | 0.150 |
Why?
|
| Hemophilia A | 1 | 2001 | 357 | 0.150 |
Why?
|
| Iatrogenic Disease | 1 | 2001 | 552 | 0.150 |
Why?
|
| Family Characteristics | 2 | 2020 | 1001 | 0.140 |
Why?
|
| Treatment Outcome | 17 | 2022 | 65223 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 4 | 2023 | 5529 | 0.140 |
Why?
|
| Health Facilities | 1 | 2022 | 577 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2013 | 1065 | 0.140 |
Why?
|
| Male | 33 | 2023 | 363740 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 14644 | 0.140 |
Why?
|
| Organizational Case Studies | 2 | 2007 | 300 | 0.140 |
Why?
|
| Child | 13 | 2021 | 80509 | 0.130 |
Why?
|
| Education, Medical, Continuing | 1 | 2021 | 830 | 0.130 |
Why?
|
| Young Adult | 12 | 2022 | 59849 | 0.130 |
Why?
|
| Social Medicine | 1 | 1996 | 64 | 0.130 |
Why?
|
| Health Priorities | 1 | 2019 | 382 | 0.130 |
Why?
|
| Child, Preschool | 11 | 2021 | 42478 | 0.130 |
Why?
|
| Africa, Southern | 2 | 2013 | 60 | 0.130 |
Why?
|
| World Health Organization | 3 | 2019 | 1326 | 0.130 |
Why?
|
| Retrospective Studies | 14 | 2019 | 81505 | 0.120 |
Why?
|
| Patient-Centered Care | 2 | 2021 | 1448 | 0.120 |
Why?
|
| Female | 30 | 2022 | 396050 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2021 | 1438 | 0.120 |
Why?
|
| Leprostatic Agents | 1 | 2014 | 13 | 0.110 |
Why?
|
| Tajikistan | 2 | 2006 | 4 | 0.110 |
Why?
|
| Cohort Studies | 10 | 2021 | 41643 | 0.110 |
Why?
|
| Infant | 7 | 2020 | 36375 | 0.100 |
Why?
|
| Virus Replication | 1 | 2021 | 2446 | 0.100 |
Why?
|
| Middle Aged | 17 | 2022 | 223016 | 0.100 |
Why?
|
| Models, Organizational | 2 | 2019 | 548 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2022 | 1349 | 0.100 |
Why?
|
| Health Personnel | 2 | 2021 | 3386 | 0.100 |
Why?
|
| Occupational Health Services | 1 | 2013 | 150 | 0.090 |
Why?
|
| Early Diagnosis | 2 | 2015 | 1187 | 0.090 |
Why?
|
| History, 20th Century | 2 | 2012 | 2761 | 0.090 |
Why?
|
| Rural Population | 3 | 2021 | 2317 | 0.090 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 123 | 0.090 |
Why?
|
| Aza Compounds | 1 | 2011 | 34 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 4056 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 4849 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 2780 | 0.090 |
Why?
|
| Drug Therapy | 1 | 2014 | 504 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2019 | 9653 | 0.090 |
Why?
|
| Prevalence | 6 | 2020 | 15832 | 0.090 |
Why?
|
| History, 19th Century | 1 | 2012 | 711 | 0.080 |
Why?
|
| Artificial Intelligence | 2 | 2022 | 2656 | 0.080 |
Why?
|
| Recurrence | 3 | 2018 | 8506 | 0.080 |
Why?
|
| Health Services Needs and Demand | 2 | 2021 | 1405 | 0.080 |
Why?
|
| International Cooperation | 1 | 2015 | 1432 | 0.080 |
Why?
|
| Disease Progression | 2 | 2019 | 13613 | 0.080 |
Why?
|
| Treatment Failure | 4 | 2018 | 2655 | 0.080 |
Why?
|
| Pneumonectomy | 1 | 2016 | 1127 | 0.080 |
Why?
|
| Aged | 8 | 2021 | 171178 | 0.080 |
Why?
|
| Algorithms | 2 | 2023 | 14062 | 0.070 |
Why?
|
| Housing | 1 | 2013 | 683 | 0.070 |
Why?
|
| Politics | 2 | 2022 | 821 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 866 | 0.070 |
Why?
|
| Risk | 2 | 2016 | 9600 | 0.070 |
Why?
|
| Health Care Costs | 3 | 2012 | 3240 | 0.070 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 961 | 0.070 |
Why?
|
| Air Ambulances | 1 | 2008 | 93 | 0.070 |
Why?
|
| USSR | 1 | 2006 | 19 | 0.070 |
Why?
|
| Symbolism | 1 | 2006 | 32 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2020 | 26337 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2012 | 1573 | 0.070 |
Why?
|
| Baltimore | 1 | 2006 | 232 | 0.060 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 937 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3435 | 0.060 |
Why?
|
| Colonialism | 1 | 2006 | 35 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2018 | 10087 | 0.060 |
Why?
|
| Quinolines | 1 | 2011 | 770 | 0.060 |
Why?
|
| Logistic Models | 4 | 2022 | 13266 | 0.060 |
Why?
|
| Hospitals | 1 | 2018 | 3887 | 0.060 |
Why?
|
| Haiti | 1 | 2006 | 553 | 0.060 |
Why?
|
| Infant Care | 1 | 2006 | 181 | 0.060 |
Why?
|
| Decision Making | 2 | 2011 | 3955 | 0.060 |
Why?
|
| United States | 3 | 2021 | 72896 | 0.060 |
Why?
|
| Rwanda | 1 | 2006 | 671 | 0.060 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2007 | 497 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6204 | 0.050 |
Why?
|
| Freedom | 1 | 2023 | 69 | 0.050 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 950 | 0.050 |
Why?
|
| Time Factors | 3 | 2014 | 40109 | 0.050 |
Why?
|
| Medication Adherence | 2 | 2012 | 2190 | 0.050 |
Why?
|
| Estonia | 2 | 2012 | 56 | 0.050 |
Why?
|
| Child Welfare | 1 | 2006 | 521 | 0.050 |
Why?
|
| Motivation | 1 | 2012 | 2018 | 0.050 |
Why?
|
| Risk Factors | 7 | 2022 | 74853 | 0.050 |
Why?
|
| Culture | 1 | 2006 | 622 | 0.050 |
Why?
|
| Alaska | 1 | 2021 | 68 | 0.050 |
Why?
|
| Capitalism | 1 | 2001 | 16 | 0.050 |
Why?
|
| Voluntary Health Agencies | 1 | 2001 | 38 | 0.050 |
Why?
|
| Anecdotes as Topic | 1 | 2001 | 56 | 0.050 |
Why?
|
| Ethambutol | 1 | 2021 | 59 | 0.050 |
Why?
|
| Comorbidity | 2 | 2013 | 10570 | 0.050 |
Why?
|
| Consumer Advocacy | 1 | 2001 | 83 | 0.050 |
Why?
|
| Consumer Product Safety | 1 | 2001 | 122 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 39226 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 59506 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2021 | 54798 | 0.040 |
Why?
|
| Computers | 1 | 2022 | 588 | 0.040 |
Why?
|
| Incidence | 4 | 2023 | 21501 | 0.040 |
Why?
|
| Policy | 1 | 2023 | 512 | 0.040 |
Why?
|
| Blood Donors | 1 | 2001 | 342 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 1084 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2012 | 3614 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 4041 | 0.040 |
Why?
|
| Quality of Life | 1 | 2020 | 13466 | 0.040 |
Why?
|
| Capreomycin | 1 | 2018 | 14 | 0.040 |
Why?
|
| Amikacin | 1 | 2018 | 48 | 0.040 |
Why?
|
| Kanamycin | 1 | 2018 | 63 | 0.040 |
Why?
|
| Morals | 1 | 2001 | 288 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2020 | 588 | 0.040 |
Why?
|
| Managed Care Programs | 1 | 2004 | 934 | 0.040 |
Why?
|
| Asia | 1 | 2020 | 628 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 3229 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 7416 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2016 | 1971 | 0.040 |
Why?
|
| Indians, North American | 1 | 2021 | 354 | 0.040 |
Why?
|
| Vitamin D | 2 | 2022 | 3272 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 1786 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 2204 | 0.040 |
Why?
|
| Intelligence | 1 | 2022 | 922 | 0.040 |
Why?
|
| Carbapenems | 1 | 2018 | 125 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2022 | 13041 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2019 | 472 | 0.030 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 12520 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2012 | 4416 | 0.030 |
Why?
|
| Smoking | 1 | 2012 | 9081 | 0.030 |
Why?
|
| Physician's Role | 1 | 2001 | 926 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2006 | 3135 | 0.030 |
Why?
|
| Boston | 1 | 2007 | 9336 | 0.030 |
Why?
|
| India | 1 | 2020 | 2333 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 7476 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2022 | 22227 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2020 | 1738 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2001 | 1672 | 0.030 |
Why?
|
| Latvia | 1 | 2012 | 15 | 0.030 |
Why?
|
| Philippines | 1 | 2012 | 95 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2001 | 1620 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 2012 | 89 | 0.020 |
Why?
|
| Georgia (Republic) | 1 | 2011 | 39 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2022 | 2115 | 0.020 |
Why?
|
| Pandemics | 2 | 2022 | 8698 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 2001 | 1311 | 0.020 |
Why?
|
| Weight Loss | 1 | 2022 | 2710 | 0.020 |
Why?
|
| ROC Curve | 1 | 2018 | 3617 | 0.020 |
Why?
|
| Drug Design | 1 | 2015 | 1040 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2011 | 426 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5302 | 0.020 |
Why?
|
| Financing, Personal | 1 | 2011 | 310 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3563 | 0.020 |
Why?
|
| Curriculum | 1 | 2021 | 3780 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2914 | 0.020 |
Why?
|
| Cross Infection | 1 | 2015 | 1425 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2021 | 3845 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6508 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2020 | 24278 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2020 | 9355 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2011 | 718 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2012 | 1740 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 1510 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8529 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2008 | 1834 | 0.010 |
Why?
|
| Data Collection | 1 | 2012 | 3317 | 0.010 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2015 | 2184 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2010 | 1241 | 0.010 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 15398 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2011 | 2595 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2011 | 2513 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 26276 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 12056 | 0.010 |
Why?
|
| Radiography | 1 | 2010 | 6941 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 29915 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 4404 | 0.010 |
Why?
|
| Age Factors | 1 | 2012 | 18380 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 8039 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 20131 | 0.010 |
Why?
|
| Pregnancy | 1 | 2015 | 30215 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 12966 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 10031 | 0.010 |
Why?
|
| Cause of Death | 1 | 2001 | 3710 | 0.010 |
Why?
|